📢It's #ESMO election time! I am delighted to be nominated for ESMO Director of Education 😊 ALL the nominees are fantastic representing the global @myesmo.bsky.social community 🌍 🙏for all the good wishes Rules this year for social media so that's it from me! Now please vote 🗳️!

We've spent 2024 discussing RT trial results in gastroesophageal cancer. My radiation oncology mate Som helps me make sense of it all below... 2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change prac.co/l/22cfph7u

When the Western really has to work (via DPhil student text) Good to see the old methods live on

Just published in #ESMOopen results from our trial of IO-naive patients with advanced kidney cancer with PD1/CTLA4 and PD1/LAG3! www.esmoopen.com/article/S205...

Twitter, as we knew it, is gone, stained by new horrific algorithms that promote misinformation. 🦋 is a much better place for those interested in science. And it’s growing fast. Thanks @jamiedoggett for highlighting our efforts to rebuild a safe place for scientific discussion.

Good to see our protocol paper for DECIPHER in press at ESMO GO! ctDNA 🧬 after surgery will detect pts with HER2➕ gastroesophageal #cancer at high risk of recurring 🧬➕ receive TDxD instead of usual post-op chemo Hope to #cure some micrometastatic cancers 🙏 www.sciencedirect.com/science/arti...

Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR! www.nature.com/articles/s41...

OS results of KN-522 out in @NEJM. Terrific news: adding pembro to neoadjuvant chemo for TNBC saves lives (5% 5-year Δ). Bad news: we’re stuck with giving 5 drugs to all patients with stage II-III TNBC, with permanent toxicity for many. Biomarkers, please! t.co/8S9YWOP1lr

Nice work from my (ex 😥) fellow @acammarota.bsky.social 👏👏 Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show: ✅Strong link between PD-L1 and pathological response. ✖️ Less so OS .. www.esmogastro.org/article/S294... Looking forward to MATTERHORN next year!

www.nature.com/articles/s41... Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang

Regular abstracts from #SABCS24 are out! 3407 pages of new breast cancer discoveries. Find them here: sabcs.org/Portals/0/Do...

ASCO annual meeting 2025 abstract submitter open - closes Jan 28th. To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)! Apply for a waiver when you submit an abstract conferences.asco.org/am/abstract-...

Best case series ever 🤣..

Looking forward to seeing the other institutions & societies join too... I've been lobbying mine 🙂

NEW #Oncology: EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization) Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models #DrugDevelopment #OncoSky www.cell.com/cell-reports...

@valdesan.bsky.social to the rescue! Oncology Vol 1 and 2 starter packs (links included in the packs) go.bsky.app/UP8aWPd #medsky #oncsky #oncosky #oncology

Good new for BTC patients!

Reclaiming our joy #MedSky #OncSky

go.bsky.app/GKXp9Fy Happy Friday! Sharing oncology starter pack #2👇

November is gastric cancer awareness month and we are sharing updates in the field ⭐ At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer. 👉See the video below! 👈 https://buff.ly/48WQh5R #stcsm #gism

Better late than never 😊👍!

Right on time for #NANETS2024: the North American Neuroendocrine Tumor Society is on @bsky.app ! Lots of posts to come from the NET community over the next three days during the Annual Symposium taking place in #Chicago. @oncothor.bsky.social @cancertrials.bsky.social @halletjulie.bsky.social

🚨The exodus of #MedTwitter #OncSky to #BlueSky @bsky.app is fascinating. All the #Twitter birds are now flying freely in the Bluesky. 🐦💙 Will #Bluesky succeed where #Threads and #Mastodon struggled?#MedTwitterMigration #BlueSkySocial @oncoalert.bsky.social @tmprowell.bsky.social

❓ Should we switch chemotherapy for patients with gastroesophageal cancer after 3 months? ARMANI trial published in Lancet Oncol today ✔️ Patients who switched to 2L pac/ram after 3m of OxFU had ⬆️ PFS and OS than patients who continued 1L chemo ❌....but also ⬆️ hospital visits & toxicity.

This oncology starter pack below👇🏼 is worth a follow.. #findyourpeople #medsky

Inspired by the other amazing starter packs - here's one for cancer researchers! I tried to make this broad - from immunology to genomics to cell biology and so much more.. This list also includes organizations & institutes supporting cancer researchers 🧪🔬⚕️🩺 Hope its useful! go.bsky.app/FEoaJMc

Once an activist, always an activist.

👏 Great to see this published! VESTIGE is a negative randomised trial with an important lesson.. ➡️ Give adjuvant FLOT even when there's residual cancer after neoadjuvant chemo. 👀 Looking forward to the translational work annalsofoncology.org/article/S0923-…